c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare disease presenting with isolated thrombocytopenia in infancy and developing into a pancytopenia in later childhood. Thrombopoietin (TPO) is the main regulator of thrombocytopoiesis and has also been demonstrated to be an important factor in early hematopoiesis. We analyzed 9 patients with CAMT for defects in TPO production and reactivity. We found high levels of TPO in the sera of all patients. However, platelets and hematopoietic progenitor cells of patients with CAMT did not show any reactivity to TPO, as measured by testing TPO-synergism to adenosine diphosphate in platelet activation or by megakaryocyte colony assays. Flow cytometric analysis revealed absent surface expression of the TPO receptor c-Mpl in 3 of 3 patients. Sequence analysis of the c-mpl gene revealed point mutations in 8 of 8 patients: We found frameshift or nonsense mutations that are predicted to result in a complete loss of c-Mpl function in 5 patients. Heterozygous or homozygous missense mutations predicted to lead to amino acid exchanges in the extracellular domain of the receptor were found in 3 other patients. The type of mutations correlated with the clinical course of the disease. We propose a defective c-Mpl expression due to c-mpl mutations as the cause for thrombocytopenia and progression into pancytopenia seen in patients with CAMT.
Ballmaier
M
M
Department of Pediatric Hematology and Oncology, Medizinische Hochschule Hannover, Germany. Ballmaier.Matthias@MH-Hannover.de
Germeshausen
M
M
Schulze
H
H
Cherkaoui
K
K
Lang
S
S
Gaudig
A
A
Krukemeier
S
S
Eilers
M
M
Strauss
G
G
Welte
K
K
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003114:Colony-Forming Units Assay; D004252:DNA Mutational Analysis; D018450:Disease Progression; D005260:Female; D005838:Genotype; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007223:Infant; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects / Q000473:pathology*; D009154:Mutation; D009363:Neoplasm Proteins; D010198:Pancytopenia / Q000209:etiology; D010766:Phosphorylation; D015539:Platelet Activation / Q000187:drug effects; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism / Q000494:pharmacology; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D015398:Signal Transduction; D013921:Thrombocytopenia / Q000151:congenital / Q000209:etiology* / Q000235:genetics; D013926:Thrombopoietin / Q000097:blood / Q000494:pharmacology
D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; D000244:Adenosine Diphosphate; D013926:Thrombopoietin